Stockscreener 앱 받기
3.11
2.20%
-0.07
전일 마감가:
$3.18
열려 있는:
$3.14
하루 거래량:
200.90K
Relative Volume:
0.22
시가총액:
$215.40M
수익:
-
순이익/손실:
$-77.22M
주가수익비율:
-1.7738
EPS:
-1.7533
순현금흐름:
$-77.27M
1주 성능:
+0.97%
1개월 성능:
+61.14%
6개월 성능:
-53.99%
1년 성능:
+142.97%
1일 변동 폭
$3.10
$3.1949
1주일 범위
$2.91
$3.30
52주 변동 폭
$1.30
$7.80
Pepgen Inc Stock (PEPG) Company Profile
명칭
Pepgen Inc
전화
703-456-8000
주소
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
3.11 | 210.20M | 0 | -77.22M | -77.27M | -1.7533 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-09 | 개시 | Guggenheim | Buy |
| 2024-12-16 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-07-31 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-21 | 개시 | H.C. Wainwright | Buy |
Pepgen Inc 주식(PEPG)의 최신 뉴스
PepGen (PEPG) Financial Update: The Bottom-Line Figure Beats Its Comparison on the Day; Trading Move - vinanet.vn
PepGen (PEPG) Financial Update: The Bottom-Line Figure Beats Its Comparison on the Day; Trading Move: Shares Finish 0.98% Higher on the DayShare Repurchase Impact - dars.gov.et
GSA Capital Partners LLP Makes New Investment in PepGen, Inc. $PEPG - MarketBeat
PEPG Q2 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress ContinuesEBITDA Analysis - Vinanet
PepGen, Inc. (NASDAQ:PEPG) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PepGen’s DM1 Bet Runs Into An FDA Hold And Dilution Fears - Finimize
PepGen Inc. (PEPG) Slips 1.17% to $2.94 as Biotech Stock Holds Above Key SupportUp Down Volume - vinanet.vn
PepGen (PEPG) Climbs 1.21% as Shares Approach Key $3.09 Resistance ZoneHigh Volume Stocks - vinanet.vn
Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation - Moomoo
PepGen identifies muscle weakness and myotonia as drivers of speech challenges in DM1 - Traders Union
HC Wainwright Has Positive Outlook of PepGen FY2027 Earnings - MarketBeat
Weekly Recap: 12.5/10 mg/kg dose escalation and Q4 2027 cash runway - TradingView
PepGen Inc. (PEPG) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of August 8, 2025 Deadline - The National Law Review
PepGen (NASDAQ:PEPG) Posts Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
PepGen Inc. Stock 12‑Month Price Target Cut to $10.19, Implies 323% Upside - TradingView
PepGen Inc (PEPG) Stock News Today - TradingKey
PepGenCash of $117.20 Mln as of June 30, 2 - Moomoo
PepGen Maintained at Buy as Analyst Cites Encouraging DM1 Safety/Efficacy Profile and Keeps $20 Price Target - TipRanks
H.C. Wainwright Maintains PepGen(PEPG.US) With Buy Rating, Maintains Target Price $20 - Moomoo
PepGen advances DM1 trial to highest dose cohort - Investing.com
PepGen Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Craig-Hallum Maintains PepGen(PEPG.US) With Buy Rating, Maintains Target Price $11 - moomoo.com
PepGen advances DM1 trial to highest dose cohort By Investing.com - Investing.com South Africa
PepGen Advances PGN-EDODM1 Trial and Strengthens Finances - TipRanks
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - biospace.com
PepGen Q2 net loss narrows as expenses fall - TradingView
PepGen Posts $17.8 Million Q2 Loss as Cash Reaches $117.2 Million - Quiver Quantitative
PepGen Inc. 1H 2026: Net loss $(35.6M), EPS $(0.51) — 10-Q Summary - TradingView
PGN-EDODM1 enters top dose group in new PepGen study - Traders Union
BRIEF-PepGen Q2 EPS USD -0.26 - TradingView
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review - Yahoo Finance
Class Action Filed Against PepGen Inc. (PEPG) Over Securities ViolationsContact Levi & Korsinsky Today - The National Law Review
PepGen Inc. (PEPG) Climbs 2.66% to $1.93 as Traders Eye Key Resistance at $2.03Revenue Growth Stocks - Vinanet
PepGen Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
Shareholders of PepGen Should Contact Faruqi & Faruqi Before August 11, 2025 to Discuss Your RightsPEPG - TMX Newsfile
PEPG Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost Discipline Amid Pipeline AdvancementRevenue Recognition Risk - vinanet.vn
PepGen: PGN-EDODM1 Multisystem Efficacy Potential Supports Buy Rating with Unchanged $20 Price Target - TipRanks
PepGen Inc. Revenue Breakdown – NASDAQ:PEPG - TradingView
PEPG Q2'26 Earnings: revenue estimate is 0 USD - TradingView
ADAR1 Capital Management LLC Purchases 1,570,796 Shares of PepGen, Inc. $PEPG - MarketBeat
PepGen Inc (PEPG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PepGen Inc (PEPG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PepGen Inc (PEPG) Cash Flow - TradingKey
Commodore Capital LP Increases Stock Position in PepGen, Inc. $PEPG - MarketBeat
Recover Investment Losses: Levi & Korsinsky Files Class Action Against PepGen Inc. (PEPG) - The National Law Review
PepGen Inc (PEPG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PepGen Inc (PEPG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PepGen Inc (PEPG) Income Statement - TradingKey
PepGen Inc (PEPG) Institutional Confidence - TradingKey
PepGen Inc (PEPG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pepgen Inc (PEPG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Pepgen Inc 주식 (PEPG) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| STRECK PAUL | EVP, Head of R&D |
Mar 04 '26 |
Sale |
6.23 |
1,879 |
11,709 |
76,226 |
| Donnelly Noel | Chief Financial Officer |
Mar 04 '26 |
Sale |
6.23 |
2,084 |
12,988 |
111,603 |
| McArthur James G | President and CEO |
Mar 04 '26 |
Sale |
6.23 |
5,275 |
32,876 |
296,326 |
| Oxford Science Enterprises plc | Former 10% Owner |
Sep 30 '25 |
Buy |
3.20 |
200,000 |
640,000 |
4,955,388 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Sep 26 '25 |
Buy |
3.20 |
9,375,000 |
30,000,000 |
18,554,273 |
0.86%
0.31%
자본화:
|
볼륨(24시간):